The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

BTOG 2021 | Highlights from BTOG 2021

Name: Highlights from BTOG 2021
Uploaded: 2021-04-23T00:00:00Z
Duration: 46 s
Description: Colin Lindsay, BSc, MBChB, MRCP, PhD, Christie NHS Foundation Trust, Manchester, UK, discusses his highlights from the BTOG 2021 meeting, commenting on the combination of immuno-oncology agents and targeted agents for the treatment of patients with lung cancer. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.

Colin Lindsay • 23 Apr 2021

BTOG 2021

Lung Cancer

Colin Lindsay, BSc, MBChB, MRCP, PhD, Christie NHS Foundation Trust, Manchester, UK, discusses his highlights from the BTOG 2021 meeting, commenting on the combination of immuno-oncology agents and targeted agents for the treatment of patients with lung cancer. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.

Disclosures

Colin Lindsay, BSc, MBChB, MRCP, PhD, has participated in an advisory role for Amgen and cbpartners; has participated in clinical trials with Amgen, Apollomics, BI, Mirati Therapeutics, Revolution Medicines and Roche; and has participated in a review paper coordinated by Amgen.